[{"id":"e3936c5c-e8c6-4488-bd75-cc3cc84c9df4","acronym":"NCI-2018-01789","url":"https://clinicaltrials.gov/study/NCT03661307","created_at":"2021-01-18T17:57:55.790Z","updated_at":"2025-02-25T15:25:53.725Z","phase":"Phase 1/2","brief_title":"Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome","source_id_and_acronym":"NCT03661307 - NCI-2018-01789","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" TP53 • FLT3","pipe":" | ","alterations":" TP53 mutation • FLT3-ITD mutation • FLT3 mutation • TP53 deletion","tags":["TP53 • FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • FLT3-ITD mutation • FLT3 mutation • TP53 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine • Vanflyta (quizartinib) • decitabine"],"overall_status":"Recruiting","enrollment":" Enrollment 73","initiation":"Initiation: 10/31/2018","start_date":" 10/31/2018","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2025-02-10"},{"id":"0586b97f-ca3e-4935-90c4-ce0d935a32d9","acronym":"NCI-2020-05261","url":"https://clinicaltrials.gov/study/NCT04493138","created_at":"2021-01-18T21:35:02.627Z","updated_at":"2024-07-02T16:34:59.952Z","phase":"Phase 1/2","brief_title":"Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations","source_id_and_acronym":"NCT04493138 - NCI-2020-05261","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" TP53 • FLT3 • ASXL1","pipe":" | ","alterations":" TP53 mutation • FLT3-ITD mutation • ASXL1 mutation • CBL mutation","tags":["TP53 • FLT3 • ASXL1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • FLT3-ITD mutation • ASXL1 mutation • CBL mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine • Vanflyta (quizartinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 58","initiation":"Initiation: 07/21/2020","start_date":" 07/21/2020","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-05-30"},{"id":"98f0842a-766f-4b08-a05c-7687c1fef2e9","acronym":"NCI-2018-01813","url":"https://clinicaltrials.gov/study/NCT01892371","created_at":"2021-01-18T08:29:57.401Z","updated_at":"2024-07-02T16:35:17.303Z","phase":"Phase 1/2","brief_title":"Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome","source_id_and_acronym":"NCT01892371 - NCI-2018-01813","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3 mutation","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • azacitidine • Vanflyta (quizartinib) • Starasid (cytarabine ocfosfate)"],"overall_status":"Completed","enrollment":" Enrollment 73","initiation":"Initiation: 11/12/2013","start_date":" 11/12/2013","primary_txt":" Primary completion: 02/07/2023","primary_completion_date":" 02/07/2023","study_txt":" Completion: 02/07/2023","study_completion_date":" 02/07/2023","last_update_posted":"2024-02-28"},{"id":"67a9166f-9a37-494a-90a4-78cf550f2b7c","acronym":"","url":"https://clinicaltrials.gov/study/NCT03793478","created_at":"2021-01-18T18:45:27.166Z","updated_at":"2024-07-02T16:35:26.615Z","phase":"Phase 1/2","brief_title":"Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood","source_id_and_acronym":"NCT03793478","lead_sponsor":"Daiichi Sankyo, Inc.","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3-ITD mutation","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • etoposide IV • Vanflyta (quizartinib) • fludarabine IV"],"overall_status":"Recruiting","enrollment":" Enrollment 65","initiation":"Initiation: 08/15/2018","start_date":" 08/15/2018","primary_txt":" Primary completion: 05/01/2027","primary_completion_date":" 05/01/2027","study_txt":" Completion: 05/01/2027","study_completion_date":" 05/01/2027","last_update_posted":"2023-12-11"},{"id":"c6a6748f-3901-4db0-9df8-1811b380e115","acronym":"QuANTUM-First","url":"https://clinicaltrials.gov/study/NCT02668653","created_at":"2021-01-18T13:00:34.703Z","updated_at":"2024-07-02T16:35:28.612Z","phase":"Phase 3","brief_title":"Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML)","source_id_and_acronym":"NCT02668653 - QuANTUM-First","lead_sponsor":"Daiichi Sankyo, Inc.","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3-ITD mutation","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • Vanflyta (quizartinib) • daunorubicin • idarubicin hydrochloride"],"overall_status":"Completed","enrollment":" Enrollment 539","initiation":"Initiation: 09/01/2016","start_date":" 09/01/2016","primary_txt":" Primary completion: 08/13/2021","primary_completion_date":" 08/13/2021","study_txt":" Completion: 06/16/2023","study_completion_date":" 06/16/2023","last_update_posted":"2023-11-20"},{"id":"54008c92-ba86-42f3-8f39-e5cbe3de14d6","acronym":"","url":"https://clinicaltrials.gov/study/NCT03735875","created_at":"2021-01-18T18:17:57.513Z","updated_at":"2024-07-02T16:35:33.514Z","phase":"Phase 1/2","brief_title":"Venetoclax and Quizartinib in Treating Patients With FLT3-mutated Recurrent or Refractory Acute Myeloid Leukemia","source_id_and_acronym":"NCT03735875","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" FLT3 • BCL2","pipe":" | ","alterations":" FLT3-ITD mutation","tags":["FLT3 • BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Vanflyta (quizartinib)"],"overall_status":"Completed","enrollment":" Enrollment 8","initiation":"Initiation: 01/25/2019","start_date":" 01/25/2019","primary_txt":" Primary completion: 07/26/2023","primary_completion_date":" 07/26/2023","study_txt":" Completion: 07/26/2023","study_completion_date":" 07/26/2023","last_update_posted":"2023-10-16"},{"id":"5d9f9f57-110b-444e-9583-1aca2af3fe7a","acronym":"VEN-A-QUI","url":"https://clinicaltrials.gov/study/NCT04687761","created_at":"2021-01-19T20:47:45.276Z","updated_at":"2024-07-02T16:36:04.261Z","phase":"Phase 1/2","brief_title":"Clinical Trial to Assess the Safety and Tolerability of the Combination of Low-dose Cytarabine or Azacitidine Plus Venetoclax and Quizartinib in Newly Diagnosed AML Patients Aged Equal or More Than 60 Years Old","source_id_and_acronym":"NCT04687761 - VEN-A-QUI","lead_sponsor":"PETHEMA Foundation","biomarkers":" IDH1 • IDH2 • NPM1","pipe":"","alterations":" ","tags":["IDH1 • IDH2 • NPM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • cytarabine • azacitidine • Vanflyta (quizartinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 84","initiation":"Initiation: 11/04/2020","start_date":" 11/04/2020","primary_txt":" Primary completion: 11/01/2024","primary_completion_date":" 11/01/2024","study_txt":" Completion: 11/01/2024","study_completion_date":" 11/01/2024","last_update_posted":"2022-09-08"},{"id":"9ec918d6-6c66-45cd-b449-933f7666cefc","acronym":"Q-SOC","url":"https://clinicaltrials.gov/study/NCT04676243","created_at":"2021-07-12T07:53:02.092Z","updated_at":"2024-07-02T16:36:09.925Z","phase":"Phase 3","brief_title":"Daunorubicin or Idarubicin With Cytarabine Plus Quizartinib vs Physician's Choice in Newly Diagnosed FLT3-ITD+ AML","source_id_and_acronym":"NCT04676243 - Q-SOC","lead_sponsor":"University Hospital Heidelberg","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3-ITD mutation • FLT3 wild-type","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation • FLT3 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • midostaurin • Vanflyta (quizartinib) • daunorubicin • idarubicin hydrochloride"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 05/01/2022","start_date":" 05/01/2022","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2022-05-25"},{"id":"798885b6-6ead-4dbb-b690-6c13e6b7ac66","acronym":"","url":"https://clinicaltrials.gov/study/NCT01411267","created_at":"2021-01-18T05:48:25.059Z","updated_at":"2024-07-02T16:36:14.134Z","phase":"Phase 1","brief_title":"AC220 for Children With Relapsed/Refractory ALL or AML","source_id_and_acronym":"NCT01411267","lead_sponsor":"Therapeutic Advances in Childhood Leukemia Consortium","biomarkers":" FLT3 • KMT2A","pipe":" | ","alterations":" MLL rearrangement","tags":["FLT3 • KMT2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MLL rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • etoposide IV • Vanflyta (quizartinib) • methotrexate"],"overall_status":"Completed","enrollment":" Enrollment 24","initiation":"Initiation: 09/01/2011","start_date":" 09/01/2011","primary_txt":" Primary completion: 09/12/2013","primary_completion_date":" 09/12/2013","study_txt":" Completion: 09/12/2013","study_completion_date":" 09/12/2013","last_update_posted":"2022-04-04"},{"id":"629de5e5-1639-4975-9979-36cefdadf496","acronym":"QuANTUM-R","url":"https://clinicaltrials.gov/study/NCT02039726","created_at":"2021-01-17T17:26:25.347Z","updated_at":"2024-07-02T16:36:34.137Z","phase":"Phase 3","brief_title":"(QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive","source_id_and_acronym":"NCT02039726 - QuANTUM-R","lead_sponsor":"Daiichi Sankyo, Inc.","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3-ITD mutation","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • Vanflyta (quizartinib)"],"overall_status":"Completed","enrollment":" Enrollment 367","initiation":"Initiation: 05/01/2014","start_date":" 05/01/2014","primary_txt":" Primary completion: 02/22/2018","primary_completion_date":" 02/22/2018","study_txt":" Completion: 09/08/2020","study_completion_date":" 09/08/2020","last_update_posted":"2021-02-24"},{"id":"c8236a79-8a25-4cee-95d2-723a44c33bea","acronym":"","url":"https://clinicaltrials.gov/study/NCT03746912","created_at":"2021-01-18T18:22:36.382Z","updated_at":"2024-07-02T16:36:45.979Z","phase":"","brief_title":"Expanded Treatment Protocol for Adults With FLT3-ITD Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) to Receive Quizartinib","source_id_and_acronym":"NCT03746912","lead_sponsor":"Daiichi Sankyo, Inc.","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3-ITD mutation","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vanflyta (quizartinib)"],"overall_status":"No Longer Available","enrollment":"","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2020-04-15"},{"id":"e757462d-c180-4124-afc4-494e35681179","acronym":"","url":"https://clinicaltrials.gov/study/NCT02984995","created_at":"2021-01-18T14:41:00.167Z","updated_at":"2024-07-02T16:36:49.969Z","phase":"Phase 2","brief_title":"Phase 2 Study of Quizartinib in Participants With Acute Myeloid Leukemia (AML) FLT3 Internal Tandem Duplication (FLT3/ITD) Mutation","source_id_and_acronym":"NCT02984995","lead_sponsor":"Daiichi Sankyo Co., Ltd.","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3-ITD mutation","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vanflyta (quizartinib)"],"overall_status":"Completed","enrollment":" Enrollment 37","initiation":"Initiation: 12/08/2016","start_date":" 12/08/2016","primary_txt":" Primary completion: 03/28/2018","primary_completion_date":" 03/28/2018","study_txt":" Completion: 09/14/2018","study_completion_date":" 09/14/2018","last_update_posted":"2020-02-17"},{"id":"3e0a6153-8b54-4405-811e-15b03e2817ea","acronym":"","url":"https://clinicaltrials.gov/study/NCT01565668","created_at":"2021-01-18T06:38:16.117Z","updated_at":"2024-07-02T16:36:52.056Z","phase":"Phase 2","brief_title":"Open Label Study to Evaluate Safety and Efficacy of 2 Doses of Quizartinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia","source_id_and_acronym":"NCT01565668","lead_sponsor":"Daiichi Sankyo, Inc.","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3-ITD mutation","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vanflyta (quizartinib)"],"overall_status":"Completed","enrollment":" Enrollment 76","initiation":"Initiation: 04/01/2012","start_date":" 04/01/2012","primary_txt":" Primary completion: 03/01/2015","primary_completion_date":" 03/01/2015","study_txt":" Completion: 03/01/2015","study_completion_date":" 03/01/2015","last_update_posted":"2019-12-27"},{"id":"432a26f3-49d8-49da-9f44-a61405932768","acronym":"","url":"https://clinicaltrials.gov/study/NCT01468467","created_at":"2021-01-18T06:06:47.201Z","updated_at":"2024-07-02T16:37:02.903Z","phase":"Phase 1","brief_title":"A Study of AC220 Given After Transplant in Subjects With Acute Myeloid Leukemia (AML)","source_id_and_acronym":"NCT01468467","lead_sponsor":"Daiichi Sankyo, Inc.","biomarkers":" HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vanflyta (quizartinib)"],"overall_status":"Completed","enrollment":" Enrollment 13","initiation":"Initiation: 04/01/2012","start_date":" 04/01/2012","primary_txt":" Primary completion: 03/01/2015","primary_completion_date":" 03/01/2015","study_txt":" Completion: 03/01/2015","study_completion_date":" 03/01/2015","last_update_posted":"2019-02-12"},{"id":"aa5fc6fc-5bfd-45a0-a705-4d1ee6bd0f8b","acronym":"","url":"https://clinicaltrials.gov/study/NCT01049893","created_at":"2021-01-18T04:07:34.262Z","updated_at":"2024-07-02T16:37:02.888Z","phase":"Phase 1","brief_title":"Dose Finding, Safety and Tolerability Study for AC220 to Treat Advanced Solid Tumors","source_id_and_acronym":"NCT01049893","lead_sponsor":"Daiichi Sankyo, Inc.","biomarkers":" KIT","pipe":"","alterations":" ","tags":["KIT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vanflyta (quizartinib)"],"overall_status":"Completed","enrollment":" Enrollment 45","initiation":"Initiation: 01/01/2010","start_date":" 01/01/2010","primary_txt":" Primary completion: 11/01/2011","primary_completion_date":" 11/01/2011","study_txt":" Completion: 11/01/2011","study_completion_date":" 11/01/2011","last_update_posted":"2019-02-12"},{"id":"ac910621-42d9-4008-be34-aeff7d6d2bbf","acronym":"","url":"https://clinicaltrials.gov/study/NCT02675478","created_at":"2021-01-18T13:02:37.896Z","updated_at":"2024-07-02T16:37:02.868Z","phase":"Phase 1","brief_title":"Phase 1 Study of Quizartinib","source_id_and_acronym":"NCT02675478","lead_sponsor":"Daiichi Sankyo Co., Ltd.","biomarkers":" FLT3","pipe":"","alterations":" ","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vanflyta (quizartinib)"],"overall_status":"Completed","enrollment":" Enrollment 17","initiation":"Initiation: 02/01/2016","start_date":" 02/01/2016","primary_txt":" Primary completion: 11/13/2018","primary_completion_date":" 11/13/2018","study_txt":" Completion: 11/13/2018","study_completion_date":" 11/13/2018","last_update_posted":"2019-02-12"},{"id":"bc4c67cc-9e30-464e-af3b-77b5c83888ef","acronym":"","url":"https://clinicaltrials.gov/study/NCT01390337","created_at":"2021-01-18T05:42:19.412Z","updated_at":"2024-07-02T16:37:02.895Z","phase":"Phase 1","brief_title":"A Study to Assess AC220 Given in Combination With Induction and Consolidation Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML)","source_id_and_acronym":"NCT01390337","lead_sponsor":"Daiichi Sankyo, Inc.","biomarkers":" FLT3 • MPO","pipe":" | ","alterations":" FLT3-ITD mutation","tags":["FLT3 • MPO"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • Vanflyta (quizartinib) • daunorubicin"],"overall_status":"Completed","enrollment":" Enrollment 19","initiation":"Initiation: 10/01/2011","start_date":" 10/01/2011","primary_txt":" Primary completion: 02/01/2015","primary_completion_date":" 02/01/2015","study_txt":" Completion: 02/01/2015","study_completion_date":" 02/01/2015","last_update_posted":"2019-02-12"}]